By analysing transcription factors (TFs) with evidence of BTLA promoter binding in ChIPseq, we found each variant tumour possessed a mutation predicted to disrupt TF binding, most frequently RUNX1/3, GATA3 and MYB (Supplementary Table 8). This evidence concerns the gene BTLA and neoplasm.